Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
Former Avila CEO Bosley signs on to lead MA's Editas
Katrine Bosley, a biotech entrepreneur known for leading Avila into a $925 million sale to Celgene ($CELG), signed on to take the helm at Editas Medicine, a gene editing company with cutting-edge technology and an all-star team to boot. Bosley joins scientists George Church, David Liu, Keith Joung, Feng Shang and Jennifer Doudna from the country's top institutions at Editas, which has pulled in a $43 million Series A round of financing. "There are rare instances when groundbreaking science comes together with a unique team, as it has at Editas, with multiple world-class institutions working in partnership to create an organization able to translate that science into groundbreaking medicines," Bosley said in a statement. "Genome editing holds the potential to impact diseases that have been untreatable, but it will also demand innovative approaches in every aspect of research, development and eventually, commercialization. It will be an incredible journey to realize that potential." Item
Biotech > Barry Lederman joined Eisai as its vice president and chief financial officer. Release > ProSensa ($RNA) announced that its CEO, Hans Schikan, has been appointed to the Biotechnology Industry Organization's (BIO) Emerging Companies Section Governing Board. Release > Cara Therapeutics ($CARA) announced that Dr. Robert Medve has been named Chief Medical Officer. Release > Advanced Cell Technology has appointed Paul Wotton as its new president and CEO. Release > ThromboGenics ($TBGNF) CFO and board member Chris Buyse has resigned. Release > Virobay has appointed James Welch as chief financial officer. Release > EpiCypher has added Sam Tetlow as CEO and a member of the company's board of directors. Release > William Jeffrey, president and CEO of HRL Laboratories, will become SRI's President and CEO effective Sept. 1. Release > InVivo Therapeutics has made three new appointments: William D'Agostino as senior vice president; Kristin Neff as vice president, clinical operations and project management; and Lisa Crockett as vice president, regulatory affairs and reimbursement planning. Release > PixarBio promoted Xi Chen to be the company's director of analytical chemistry and Haining Dai as its director of preclinical neuroscience. Release > Voyager Therapeutics appointed Robert Pietrusko as its senior vice president of regulatory affairs. Release > Senesco Technologies appointed Ronald Martell as its CEO at this year's BIO convention. Release > Summit Corporation named Erik Ostrowski as its chief financial officer. Release > XBiotech announced that it brought on Gary Gonzales as its vice president of clinical operations. Release > N8 Respiratory named Bruce Halpryn as its chief operating officer. Release > Pernix Therapeutics appointed Sanjay Patel as its chief financial officer. Release > Krista Roberts joined Noven as its vice president of operations. Release > Lion Biotechnologies appointed Laszlo Radvanyi as its chief scientific officer. Release > Versartis appointed endocrinologist Bert Bakker as its senior vice president of medical affairs. Release Pharma > Sally Berry and Norma Cappetti joined Tris Pharma as chief medical officer and vice president of regulatory affairs, respectively. Release > Cipher Pharmaceuticals brought on Shawn O'Patrick, formerly of AltheRx, to be the company's Cipher. Release > Anthera Pharmaceuticals ($ANTH) has appointed Brian R. Mueller to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors. Release > Merck ($MRK) named Michael Holston as its future general counsel to succeed Bruce Kuhlick in July, 2015. Release > Actavis ($ACT) appointed C. David Nicholson to head its global brands research and development. Release Diagnostics > Concord Medical's board of directors has appointed Yaw Kong Yap as the new chief financial officer and Adam Jigang Sun as the chief investment officer. Release |
||||||||||
